Gene

MERTK

MER proto-oncogene, tyrosine kinase

Explore in graph →CI-GENE-00012401HGNC:7027 ENSG00000153208 NCBI 10461 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MERTK OVEREXPRESSION1
UNC1062	Melanoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID2991 Highest MERTK expression was observed in metastatic melanomas, followed by primary melanomas, and lowest in benign nevi. Over half of melanoma cell lines overexpressed MERTK compared with normal human… (full text at CIViC) PMID 23585477 · Schlegel et al., 2013 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (6)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved6 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Adenoid Cystic Carcinoma (JHU, Cancer Prev Res 2016) acyc_jhu_2016	Adenoid Cystic Carcinoma	Ssm	1	25

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
· J Clin Invest · 2013 · PMID 23585477 · validated civic_curation pubmed